Table 3.
Extent of biomarker staining agreement between biopsy and hysterectomy.
| Marker | Concordant biopsy and hysterectomy |
Discordant biopsy and hysterectomy |
||||
|---|---|---|---|---|---|---|
| Bx+/Hyst+ | Bx-/Hyst- | Bx+/Hyst- | Bx-/Hyst+ | Agreement (95% CI) | Kappa (p) | |
| (a) | ||||||
| P-AKT | 8 | 4 | 4 | 2 | 67% (41–87%) | 0.31 (p = .09) |
| ER | 11 | 5 | 3 | 1 | 80% (56–94%) | 0.57 (p = .005) |
| PR | 6 | 8 | 3 | 2 | 73% (49–91%) | 0.47 (p = .02) |
| EGFR | 5 | 10 | 3 | 0 | 83% (59–96%) | 0.65 (p = .002) |
| Her2/neu | 20 | 0 | 0 | 0 | 100% (83–100%) | n/a |
| PTEN loss | 19 | 0 | 1 | 0 | 95% (75–100%) | n/a |
| (b) Intensity of biomarker staining agreement between biopsy and hysterectomy | ||||||
| P-AKT | 8 | 3 | 5 | 2 | 61% (36–83%) | 0.18 (p = .2) |
| ER | 11 | 5 | 3 | 1 | 80% (56–94%) | 0.57 (p = .005) |
| PR | 6 | 8 | 3 | 2 | 74% (49–91%) | 0.47 (p = .02) |
| EGFR | 5 | 10 | 3 | 0 | 83% (57–96%) | 0.65 (p = .002) |
| Her2/neu | 20 | 0 | 0 | 0 | 100% (83–100%) | n/a |
| PTEN loss | 19 | 0 | 0 | 0 | 100% (82–100%) | n/a |